stoxline Quote Chart Rank Option Currency Glossary
  
Genelux Corporation (GNLX)
6.43  0.41 (6.81%)    03-28 16:00
Open: 5.94
High: 6.44
Volume: 66,217
  
Pre. Close: 6.02
Low: 5.9
Market Cap: 172(M)
Technical analysis
2024-03-28 4:51:45 PM
Short term     
Mid term     
Targets 6-month :  8.78 1-year :  10.12
Resists First :  7.52 Second :  8.66
Pivot price 6.22
Supports First :  5.67 Second :  4.71
MAs MA(5) :  6.15 MA(20) :  6.35
MA(100) :  10.66 MA(250) :  19.66
MACD MACD :  -0.6 Signal :  -0.8
%K %D K(14,3) :  31.3 D(3) :  28
RSI RSI(14): 43.2
52-week High :  40.97 Low :  5.67
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ GNLX ] has closed below upper band by 27.8%. Bollinger Bands are 77.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 6.45 - 6.47 6.47 - 6.5
Low: 5.84 - 5.86 5.86 - 5.89
Close: 6.38 - 6.42 6.42 - 6.47
Company Description

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Headline News

Mon, 25 Mar 2024
Advisor Resource Council Acquires New Stake in Genelux Co. (NASDAQ:GNLX) - Defense World

Sun, 24 Mar 2024
Whittier Trust Co. of Nevada Inc. Invests $100000 in Genelux Co. (NASDAQ:GNLX) - Defense World

Fri, 15 Mar 2024
Genelux Co. (NASDAQ:GNLX) Short Interest Update - MarketBeat

Tue, 05 Mar 2024
GNLX Stock Quote Price and Forecast - CNN

Tue, 06 Feb 2024
Genelux Corp. Unveils Future-Oriented Corporate Presentation - TipRanks.com - TipRanks

Fri, 05 Jan 2024
La Sierra Business School Dean Brings Venture’s Success to the Classroom - Adventist Review

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 27 (M)
Held by Insiders 2.018e+007 (%)
Held by Institutions 22.4 (%)
Shares Short 1,110 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.972e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -8 %
Return on Assets (ttm) 511.7 %
Return on Equity (ttm) -63 %
Qtrly Rev. Growth 238000 %
Gross Profit (p.s.) 0.42
Sales Per Share 0.42
EBITDA (p.s.) -0.31
Qtrly Earnings Growth -1.1 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -15 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 14.97
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 1.59e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android